医学
心力衰竭
阻塞性睡眠呼吸暂停
射血分数
内科学
心脏病学
非酒精性脂肪肝
2型糖尿病
代谢综合征
糖尿病
射血分数保留的心力衰竭
心肾综合症
睡眠呼吸暂停
内分泌学
疾病
脂肪肝
作者
Vincenzo Maria Monda,Sandro Gentile,Francesca Porcellati,Ersilia Satta,Alessandro Fucili,Marcello Monesi,Felice Strollo
标识
DOI:10.1007/s12325-022-02310-2
摘要
After examining the complex interplay between heart failure (HF) in its various clinical forms, metabolic disorders like nonalcoholic fatty liver disease (NAFLD), and obstructive sleep apnea (OSA) syndrome, in this mini-review we described possible favorable effects of sodium–glucose cotransporter 2 inhibitors (SGLT2is) on HF with preserved (i.e., ≥ 50%) ejection fraction (HFpEF) through enhanced cardiorenal function and visceral-subcutaneous body fat redistribution. In greater detail, on the basis of pathophysiological mechanisms underlying OSA onset and the direct positive SGLT2i effect on renal function benefiting chronic kidney disease, we emphasized the promising role of SGLT2is in prevention, rehabilitation, and treatment of patients with OSA regardless of coexisting type 2 diabetes (T2DM). Indeed, SGLT2is enhance lipolysis and fatty acid beta-oxidation. These phenomena might prevent OSA by reducing the size of visceral and subcutaneous adipose tissue and, as proven in humans and animals with T2DM, counteract NAFLD onset and progression. The aforementioned mechanisms may represent an additional SGLT2i cardioprotective effect in terms of HFpEF prevention in patients with OSA, whose NAFLD prevalence is estimated to be over 50%.
科研通智能强力驱动
Strongly Powered by AbleSci AI